|
Mutually exclusive expression of CD73 and PDL1 in tumors from patients (pt) with NSCLC, gastroesophageal (GE) and urothelial bladder carcinoma (UBC). |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Research Funding - MedImmune |
|
|
|
|
|
No Relationships to Disclose |
|
|
|
|
|
|
Stock and Other Ownership Interests - Definiens |
|
|
|
Patents, Royalties, Other Intellectual Property - Definiens |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - MedImmune |
Research Funding - MedImmune |
Patents, Royalties, Other Intellectual Property - MedImmune |
|
|
No Relationships to Disclose |
|
|
Employment - MedImmune; MedImmune |
Stock and Other Ownership Interests - MedImmune; MedImmune |
Consulting or Advisory Role - MedImmune (I) |
Patents, Royalties, Other Intellectual Property - MedImmune |